First Trust Advisors’s Viking Therapeutics VKTX Stock Holding History

First Trust Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.44M	Buy	113,751 +8,181	+8%	+$264K	﹤0.01%	1654
2026 Q1	$3.44M	Buy	+105,570	New	+$3.39M	﹤0.01%	1669
2024 Q4	–	Sell	-12,283	Closed	-$778K	–	2648
2024 Q3	$778K	Buy	+12,283	New	+$721K	﹤0.01%	2074
2022 Q3	–	Sell	-102,755	Closed	-$297K	–	2615
2022 Q2	$297K	Sell	102,755 -4,173	-4%	-$10.3K	﹤0.01%	2305
2022 Q1	$321K	Sell	106,928 -6,022	-5%	-$21.6K	﹤0.01%	2360
2021 Q4	$520K	Buy	112,950 +14,014	+14%	+$78.5K	﹤0.01%	2279
2021 Q3	$621K	Buy	+98,936	New	+$611K	﹤0.01%	2212

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

First Trust Advisors's VKTX Position: Q2 2026 in Review

First Trust Advisors increased its Viking Therapeutics (VKTX) stake by 7.7% in Q2 2026, buying an estimated $264K and bringing the position to 113,751 shares worth $4.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1654.

First Trust Advisors first reported a position in VKTX in Q3 2021 and has held it in 7 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

First Trust Advisors held 113,751 shares of Viking Therapeutics worth $4.44M as of Q2 2026.
First Trust Advisors bought 8,181 Viking Therapeutics shares in Q2 2026, an estimated $264K.
Viking Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1654 holding.
First Trust Advisors first reported a position in Viking Therapeutics in Q3 2021 and has held it in 7 quarters since.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.